Stimulation of human monocytes by anti-CD3 monoclonal antibody: induction of inflammatory mediator release via immobilization of Fc receptor by adsorbed immunoglobulin and T-lymphocytes
- PMID: 1334047
- DOI: 10.1007/BF00919341
Stimulation of human monocytes by anti-CD3 monoclonal antibody: induction of inflammatory mediator release via immobilization of Fc receptor by adsorbed immunoglobulin and T-lymphocytes
Abstract
Human monocytes released superoxide anion, prostaglandin E2, leukotriene B4, IL-1, and TNF when exposed to plastic surfaces coated with murine anti-CD3 monoclonal antibody, OKT 3. Stimulation of mediator release by OKT 3 was dependent on the amount of antibody immobilized onto wells of plastic tissue culture plates. Soluble antibody or antibody adsorbed to monocytes and reacted with an aggregating ("cross-linking") second antibody failed to induce mediator release. Monocytes "armed" with OKT 3 formed rosettes with T cells in a fashion indistinguishable from that seen between monocytes and T cells sensitized with OKT 3. Monocytes with adsorbed OKT 3 antibodies released IL-1 beta and TNF-alpha when exposed to unsensitized T cells, although increased superoxide release could not be detected. OKT 4a, a murine IgG2a antibody that reacts with a different T cell epitope (CD4), failed to induce cytokine release from monocytes when cross-linked by T cells or a CD4+ T cell line, even in the presence of IL-2 or IFN-gamma. These data indicate that certain antibodies bound to Fc receptors (FcR) of monocytes may trigger monocyte function when reacting with cells bearing the appropriate target antigens. FcR-mediated signaling resulting in mediator release may be involved in initiating or regulating the immune response. Furthermore, systemically administered monoclonal antibodies may induce inflammatory responses and their attendant symptomatologies via their interaction with FcR-bearing inflammatory cells.
Similar articles
-
Inflammatory mediator release from human monocytes via immobilized Fc receptors. Its potential role in adverse reactions to systemic monoclonal antibody therapy.Transplantation. 1992 Aug;54(2):343-6. doi: 10.1097/00007890-199208000-00027. Transplantation. 1992. PMID: 1323151
-
Interferon-gamma restores T lymphocyte proliferation of nonresponders to IgG1 anti-CD3 via the induction of Fc gamma 1 receptors on monocytes.Eur J Immunol. 1987 Aug;17(8):1175-81. doi: 10.1002/eji.1830170815. Eur J Immunol. 1987. PMID: 2957217
-
Human T cell activation induced by a monoclonal mouse IgG3 anti-CD3 antibody (RIV9) requires binding of the Fc part of the antibody to the monocytic 72-kDa high-affinity Fc receptor (FcRI).Cell Immunol. 1989 Jan;118(1):136-46. doi: 10.1016/0008-8749(89)90363-8. Cell Immunol. 1989. PMID: 2521302
-
T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs.Curr Opin Immunol. 1997 Oct;9(5):648-54. doi: 10.1016/s0952-7915(97)80044-1. Curr Opin Immunol. 1997. PMID: 9368773 Review.
-
Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes.Ann N Y Acad Sci. 2004 Dec;1037:1-9. doi: 10.1196/annals.1337.001. Ann N Y Acad Sci. 2004. PMID: 15699486 Review.
Cited by
-
Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.Drugs. 1996 May;51(5):865-94. doi: 10.2165/00003495-199651050-00010. Drugs. 1996. PMID: 8861551 Review.
-
The frequency of interleukin-1β-producing monocytes is significantly associated with varicella-zoster responses of nursing home residents.Clin Exp Immunol. 2021 Jul;205(1):63-74. doi: 10.1111/cei.13593. Epub 2021 Apr 4. Clin Exp Immunol. 2021. PMID: 33714219 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Research Materials